Progestogens for Prevention of Preterm Birth
Summary of Benefits: According to Indication/Risk Group (2 of 3)
Women with short cervix may benefit from progestogen treatment, but the size of the effect is not established. The strength of evidence for this conclusion is low.
In women with twin or triplet pregnancies there is no benefit of progestogen treatment. Moderate-strength evidence indicates that birth is not delayed. Moderate-strength evidence indicates that birth weights are not improved. The evidence about mortality rates is insufficient to permit a summary estimate of the effect.
Keywords: preterm birth | progesterone | progestogens | progestins | preterm labor | birth weight | fetal death rate | neonatal death rate | neonatal mortality | fetal mortality | 37 weeks | multiple gestations | twins | triplets | short cervix
- Likis FE, Andrews JC, Woodworth AL, et al. Effectiveness of Progestogens for Prevention of Preterm Birth. Comparative Effectiveness Review No. 74 (Prepared by the Vanderbilt Evidence-based Practice Center under Contract No. 290-2007-10065-I). Rockville, MD: Agency for Healthcare Research and Quality; September 2012. AHRQ Publication No. 12-EHC105-EF. Available at www.effectivehealthcare.ahrq.gov/pretermbirth.cfm.
Your slide tray is being processed.